Teague Joanne, Gyte Amie, Peel Joanne E, Young Kimberley C, Loxham Susan J G, Mayers Rachel M, Poucher Simon M
CVGI Discovery, AstraZeneca, Alderley Park, Macclesfield, Cheshire, UK.
J Pharmacol Toxicol Methods. 2011 Jan-Feb;63(1):15-23. doi: 10.1016/j.vascn.2010.04.001. Epub 2010 Apr 14.
We characterised the development of Type 2 diabetes and associated changes in islet appearance in female ZDF rats and explored its suitability for studies with novel therapeutic agents.
Female ZDF rats were either chow or high fat (60%) fed for up to 36 days and blood glucose and plasma insulin concentration measured. Additionally, we restored two groups of rats back to chow diet after ten and nineteen days of high fat feeding to determine the reversibility. Finally, two other groups of high fat-fed animals were dosed either orally with drug vehicle or had a minipump implanted subcutaneously to determine the effect of dosing method upon the progression of this disease model. The beta cell mass and morphology were assessed by immunohistochemistry for insulin.
High fat feeding elevated blood glucose compared to chow-fed controls which peaked by 15 days, and maintained throughout the study. Plasma insulin reached a maximum after 8 days, but declined over the remaining 4 weeks. Assessment of islets revealed marked disruption, dispersion and weaker insulin staining. The area and percentage β-cells were higher in high fat-fed animals. High fat diet treatment reversal when animals were moderately hyperglycaemic, when plasma insulin was still elevated, reversed the hyperglycaemia and maintained islet morphology similar to that of chow-fed animals. In contrast, dietary reversal when plasma insulin was declining, did not prevent continual decline in plasma insulin, β-cell mass or islet disruption. Oral dosing tended to increase blood glucose and decrease plasma insulin whereas administration by minipump lowered blood glucose.
The obese female ZDF rat offers the opportunity for preclinical evaluation of novel therapies directed towards improving pancreatic function, provided treatment is initiated prior to the precipitous decline in insulin production. Caution should be exercised in comparison of compounds administered by different dosing routes however.
我们对雌性ZDF大鼠2型糖尿病的发展及胰岛外观的相关变化进行了特征描述,并探讨了其对新型治疗药物研究的适用性。
将雌性ZDF大鼠分为两组,分别给予普通饲料或高脂(60%)饲料喂养长达36天,并测量血糖和血浆胰岛素浓度。此外,我们在高脂喂养10天和19天后,将两组大鼠恢复为普通饲料喂养,以确定其可逆性。最后,另外两组高脂喂养的动物分别口服药物载体或皮下植入微型泵,以确定给药方式对该疾病模型进展的影响。通过胰岛素免疫组织化学评估β细胞质量和形态。
与普通饲料喂养的对照组相比,高脂喂养使血糖升高,在15天时达到峰值,并在整个研究过程中保持。血浆胰岛素在8天后达到最大值,但在接下来的4周内下降。胰岛评估显示明显的破坏、分散和胰岛素染色减弱。高脂喂养动物的β细胞面积和百分比更高。当动物处于中度高血糖状态且血浆胰岛素仍升高时,高脂饮食治疗逆转可使高血糖逆转,并维持与普通饲料喂养动物相似的胰岛形态。相比之下,当血浆胰岛素下降时进行饮食逆转,并不能阻止血浆胰岛素、β细胞质量或胰岛破坏的持续下降。口服给药倾向于使血糖升高并降低血浆胰岛素,而通过微型泵给药则可降低血糖。
肥胖雌性ZDF大鼠为针对改善胰腺功能的新型疗法提供了临床前评估的机会,前提是在胰岛素分泌急剧下降之前开始治疗。然而,在比较不同给药途径的化合物时应谨慎。